Today: 21 May 2026
Browse Category

Growth Stocks 9 December 2025 - 12 May 2026

RKLB Stock Pulls Back After Breakout as Neutron Demand Starts to Set the Price

RKLB Stock Pulls Back After Breakout as Neutron Demand Starts to Set the Price

Rocket Lab shares fell 2.4% to $114.58 Tuesday after hitting an all-time high of $123.94 Monday, following a 40% rally last week. The company reported Q1 revenue of $200.3 million, a $2.2 billion backlog, and more launch contracts booked in three months than in all of 2025. Investors cited both profit-taking and continued bullish sentiment on Neutron and defense demand.
12 May 2026
···
Hims & Hers’ GLP-1 Reset Hits the Stock as Investors Reprice Growth Quality

Hims & Hers’ GLP-1 Reset Hits the Stock as Investors Reprice Growth Quality

Hims & Hers Health shares fell 14.6% to $24.89 Tuesday after a Q1 net loss of $92.1 million, reversing a $49.5 million profit a year ago. Revenue rose 4% to $608.1 million, but gross margin dropped to 65% from 73% as the company shifted from compounded GLP-1s to branded drugs like Wegovy and Ozempic. Subscribers climbed to 2.584 million, while monthly revenue per subscriber slipped to $80.
12 May 2026
··
AI Stocks With Growth Potential in Q2 2026: The 5 Names Wall Street Is Testing After the OpenAI Shock

AI Stocks With Growth Potential in Q2 2026: The 5 Names Wall Street Is Testing After the OpenAI Shock

AI-related stocks fell Tuesday after a report on OpenAI’s missed targets hit Oracle, CoreWeave, and chipmakers. Nvidia, AMD, and Broadcom dropped between 1.6% and 4.4%, while CoreWeave slid 5.8%. Alphabet, Microsoft, Meta, and Amazon are set to report earnings Wednesday, with about $600 billion in AI spending under scrutiny. Investors are watching for direct revenue tied to chips, cloud, and custom silicon.
29 April 2026
··········
Top 10 Growth Stocks to Watch in Q2 2026 as AI Spending Faces Its Hardest Test Yet

Top 10 Growth Stocks to Watch in Q2 2026 as AI Spending Faces Its Hardest Test Yet

Microsoft, Alphabet, Amazon, and Meta are set to report earnings Wednesday, with investors watching for signs that heavy AI spending is driving growth. Visa posted a 17% rise in net revenue to $11.2 billion and announced a $20 billion buyback. T-Mobile raised 2026 guidance after service revenue climbed 11%. U.S. stocks fell Tuesday, with the Nasdaq down 0.90% as tech shares slipped.
29 April 2026
············
SoFi stock price slides 5% as risk-off hits growth names; what traders watch next

SoFi stock price slides 5% as risk-off hits growth names; what traders watch next

SoFi Technologies shares dropped 5.3% to $19.65 Thursday afternoon, extending losses despite a JPMorgan upgrade earlier this week. Investors reacted to SoFi’s 2026 growth targets and a broader selloff in fintech and consumer-lending stocks. Affirm and Upstart also fell sharply. Attention shifts to next week’s delayed U.S. jobs and inflation data for clues on interest rates.
5 February 2026
··
Palantir Stock Gets Fresh $208 Buy Call — But Can It Grow Fast Enough?

Palantir Stock Gets Fresh $208 Buy Call — But Can It Grow Fast Enough?

Phillip Securities began coverage of Palantir Technologies with a “Buy” rating and a $208 price target, as shares traded near $165. The move comes amid debate over Palantir’s high valuation and rapid AI-driven growth. Some analysts warn the company must sustain 30–40% annual revenue growth to justify current prices. CEO Alex Karp has dismissed valuation concerns.
22 January 2026
·
AppLovin (NASDAQ: APP) stock dips today as year-end tech pullback pressures growth names

AppLovin (NASDAQ: APP) stock dips today as year-end tech pullback pressures growth names

AppLovin shares fell 1.3% to $685 in thin year-end trading Wednesday, underperforming major indexes as investors rotated out of high-growth tech stocks. Treasury yields rose after jobless claims dropped to 199,000, pressuring growth shares further. The Invesco QQQ Trust and S&P 500-tracking SPDR fund each slipped about 0.2% in afternoon trading.
31 December 2025
···
Wingstop (WING) Stock on December 11, 2025: Price Drop, Q3 Slowdown and Whether the Chicken Chain Is Still a Growth Story

Wingstop (WING) Stock on December 11, 2025: Price Drop, Q3 Slowdown and Whether the Chicken Chain Is Still a Growth Story

Wingstop shares fell about 5% to $234.46 on December 11, 2025, extending a year-to-date drop of nearly 15%, despite continued revenue and net income growth. Q3 results showed system-wide sales up 10% and adjusted EPS beating estimates, but domestic same-store sales dropped 5.6%, the steepest fall in five years.
11 December 2025
····
The Trade Desk (TTD) Stock on December 11, 2025: New 52‑Week Lows, Bullish Forecasts and a High‑Stakes 2026 Rebound Bet

The Trade Desk (TTD) Stock on December 11, 2025: New 52‑Week Lows, Bullish Forecasts and a High‑Stakes 2026 Rebound Bet

The Trade Desk shares fell to $37.06 on December 11, down about 70% over the past year despite double-digit revenue and profit growth. The company reported Q3 revenue of $739 million, up 17–18% year over year, with $1.4 billion in cash and no debt. Wall Street analysts remain bullish, but options traders are bearish. Investor Cathie Wood has been buying shares.
11 December 2025
··
SoFi Technologies (SOFI) Stock Forecast 2025–2030: Can the Fintech Darling Keep Climbing After Its 100% Rally?

SoFi Technologies (SOFI) Stock Forecast 2025–2030: Can the Fintech Darling Keep Climbing After Its 100% Rally?

SoFi Technologies shares traded around $27 midday December 11, up about 100% year-to-date, after surging from $25.19 on November 21 to $29.72 by November 28. The company announced a $1.5 billion share offering amid record earnings and rapid member growth. Wall Street’s 12-month consensus target is $26.97, with analyst targets ranging from $3 to $37.
11 December 2025
··
Robinhood (HOOD) Stock Outlook After November 21, 2025: Can a 260%+ Rally Keep Running Into 2026?

Robinhood (HOOD) Stock Outlook After November 21, 2025: Can a 260%+ Rally Keep Running Into 2026?

Robinhood closed at $135.66 on December 10, 2025, up about 26% since November 21. Q3 revenue doubled to $1.27 billion, with net income at $556 million. November saw 26.9 million funded customers and $324.5 billion in assets, but Connecticut regulators have issued cease-and-desist orders over event contracts. Analysts remain broadly bullish, though price targets cluster near current levels.
11 December 2025
··
Best UK Stocks to Buy Now (11 December 2025): 9 FTSE Shares for 2026 Growth, Income and Value

Best UK Stocks to Buy Now (11 December 2025): 9 FTSE Shares for 2026 Growth, Income and Value

The FTSE 100 hovered near record highs around 9,600–9,700 on December 11, 2025, after a strong rally led by banks, energy, miners, and defense stocks. Despite a 22.8% total return for the year, UK equities remain valued below global peers at about 12.5 times 2026 earnings. Inflation has eased to the mid-3% range, and the Bank of England’s base rate sits near 4% after earlier cuts. Investors remain cautious as European shares dip and tech stocks weaken.
11 December 2025
··
Best ASX Stocks to Buy Now (December 11, 2025): Top Australian Shares for 2026 Growth & Income

Best ASX Stocks to Buy Now (December 11, 2025): Top Australian Shares for 2026 Growth & Income

The ASX 200 is up about 5.4% in 2025, trading near 8,600 and on track for a third consecutive annual gain. The index’s forward P/E stands at 18.1, above its long-term average. Major banks project further gains in 2026, with UBS targeting 8,900 and Morgan Stanley 9,250, citing strength in resources. Materials have surged 24.5% this year, while healthcare and IT lag.
11 December 2025
······
Boston Scientific (BSX) Stock on December 10, 2025: Why Shares Are Sliding While the Growth Story Stays Intact

Boston Scientific (BSX) Stock on December 10, 2025: Why Shares Are Sliding While the Growth Story Stays Intact

Boston Scientific shares closed at $92.53 on December 9, down 1.4% and marking a seventh straight decline, with trading volume spiking to 12.7 million shares. The stock sits about 15% below its September high despite strong Q3 results, including 20% year-over-year sales growth and adjusted EPS of $0.75, beating forecasts. Over the past year, BSX remains slightly positive and is up about 170% over five years.
10 December 2025
··
Best UK Stocks to Buy Now (10 December 2025): 8 FTSE Shares for Growth, Income & Recovery

Best UK Stocks to Buy Now (10 December 2025): 8 FTSE Shares for Growth, Income & Recovery

The FTSE 100 rose yesterday as gains in BAE Systems and Rolls-Royce offset losses in British American Tobacco. Investors are positioning for possible rate cuts in 2026, with UK inflation down to 3.6% in October. The Bank of England expects the upcoming budget to further reduce inflation and says banks remain resilient. FTSE 100 companies are set to repurchase about £56.6bn in stock this year.
10 December 2025
······
Carvana (CVNA) Soars Toward S&P 500 Debut – Is the 8,000% Rally Still Sustainable in 2025?

Carvana (CVNA) Soars Toward S&P 500 Debut – Is the 8,000% Rally Still Sustainable in 2025?

Carvana shares closed at $447.98 on December 8, up 12% for the day and near record highs, after news it will join the S&P 500 on December 22. The company’s market value now stands around $87–97 billion, surpassing Ford and GM. Carvana’s stock has surged over 8,000% since 2022 lows. Analysts remain split on whether the valuation is sustainable.
9 December 2025
···
Tokyo Stock Market’s Biggest Losers Today (December 9, 2025): Growth, Biotech and Small Caps Take the Hit

Tokyo Stock Market’s Biggest Losers Today (December 9, 2025): Growth, Biotech and Small Caps Take the Hit

Tokyo’s Nikkei 225 rose 0.2% to around 50,700 Tuesday, bucking declines in other Asian markets. Small- and mid-cap stocks on the Tokyo Stock Exchange slumped 8–14%, with biotech and growth shares leading losses. A 7.5-magnitude earthquake and central bank uncertainty weighed on sentiment. The yen briefly weakened after the quake; authorities reported about 30 injuries.
9 December 2025
·
1 2 3

Stock Market Today

  • SpaceX IPO Filing Reveals Financials, Musk Could Become First Trillionaire
    May 20, 2026, 7:08 PM EDT. SpaceX filed for an initial public offering (IPO), disclosing its finances and board members for the first time. The company reported $18.7 billion in revenue for 2025, up 33% year-on-year, but posted a net loss of $4.9 billion, reversing a $791 million profit in 2024. First-quarter 2026 losses reached $4.3 billion on $4.7 billion revenue. The IPO, trading as SPCX, may become the largest ever, potentially boosting Elon Musk's wealth to trillionaire status. SpaceX aims to fund its ambitious plans including Starlink satellite network expansion, AI infrastructure, and establishing extraterrestrial colonies.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop